PhysioSonics announced the U.S. Food and Drug Administration (FDA) has granted the Presto 1000 Flow Monitor system 510(k) clearance for cranial blood flow monitoring. In addition, the company announced completion of Series B add-on debt financing, closing with $1.05 million.
A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain — and can also experience their relief following treatment.
The American College of Cardiology (ACC) and the American Heart Association (AHA) released a set of key data elements and definitions for the clinical management of patients with acute coronary syndromes (ACS) and coronary artery disease (CAD). Drafted with the primary goal of aiding data collection, the new standards should ultimately help compare data among different studies, promote the interoperability and applicability of electronic health records (EHRs) and facilitate the adoption of research to clinical practice.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
January 31, 2013 — Cardiovascular Systems Inc. (CSI) announced CONFIRM study series data presented at the 2013 International Symposium on Endovascular Therapy (ISET).
Biosensors International has announced CE mark approval for its polymer-free drug-coated stent (DCS), BioFreedom.
January 31, 2013 — Belgian biotechnology company Cardio3 BioSciences (C3BS) announced it has received authorization to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European phase III trial for C3BS-CQR-1 in Belgium.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Coronary artery disease and peripheral artery disease are global health issues that affect millions of lives each year, and bioabsorbable stents are due to become the next step in treatment once the medical world has provided enough clinical data and prices are lowered, states a new report by research and consulting firm GlobalData.
January has been a month of change for Abbott, and a senior medical devices analyst from GlobalData asserts that the company’s latest cardiac diagnostics product represents the first step in a line of new diagnostic products that will act to deliver growth over the next few years.
Fujifilm Medical Systems U.S.A. Inc. shared the benefits of its zero footprint mobile application, Synapse Mobility, with visitors to the 2012 meeting of the Radiological Society of North America (RSNA). The application enables access to Fujifilm’s suite of Synapse products from hand-held devices, in addition to Macintosh- or Windows-based PCs. It was one of several Synapse products and solutions demonstrated at the show.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
St. Jude Medical Inc. announced European CE mark approval of its Amplatzer Amulet Left Atrial Appendage Occluder. The Amulet device is used to close the left atrial appendage (LAA) in patients diagnosed with non-valvular atrial fibrillation (AF). According to research, AF leads to an increased risk for stroke. Sealing off the LAA helps prevent the risk of blood clot formation and release, potentially reducing the risk of stroke. The next-generation percutaneous transcatheter device leverages the design and clinical success of the original Amplatzer Cardiac Plugwith additional features allowing treatment of a wider range of appendage anatomies. St. Jude Medical will be showcasing the new Amplatzer Amulet device during the 18th annual Boston AF Symposium at booth 319.
Epiphany has received the “Category Leader” recognition in ECG Management from KLAS for the fourth consecutive year.
An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes. Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott announced CE marking for the Architect Stat High Sensitive Troponin-I Assay.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
To help identify trends and find out what DAIC readers are interested in, the magazine takes note of what they click on when visiting the website. Below are the top 25 stories from 2012, and the top 10 stories read in 2012 that were written in previous years.
In a study designed to see if doctors who are told the exact price of expensive medical tests like magnetic resonance imaging (MRI) in advance would order fewer of them, Johns Hopkins researchers got their answer: No.
According to Millennium Research Group (MRG), increasing awareness and diagnosis of peripheral vascular disease (PVD) along with the introduction of improved next-generation devices will lead the United States peripheral vascular (PV) device market to grow strongly to reach $3.3 billion by 2017.